Bayer AG’s Real-World Study on Vericiguat: Implications for Heart Failure Treatment in Japan

Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.

Bayer AG is conducting an observational study titled ‘ROVER Japan/ Real-world Outcomes of Patients Treated With Vericiguat in Japanese Routine Care: a Retrospective Cohort Study Using a Hospital Administrative Database.’ The study aims to gather real-world data on the effectiveness of vericiguat, a drug used to treat chronic heart failure with reduced ejection fraction (HFrEF) in Japan. The study is significant as it seeks to fill the gap in real-world data for vericiguat’s use in Japanese patients, potentially influencing treatment protocols and outcomes.

The intervention being tested is vericiguat, a drug designed to enhance the activity of soluble guanylate cyclase (sGC), which helps relax blood vessels and improve heart function. Vericiguat is already approved for use in Japan for patients with chronic HFrEF.

This study is observational and retrospective, focusing on a cohort of patients who have newly initiated treatment with vericiguat. It does not involve any new interventions or masking, as it relies on existing data from hospital records to assess outcomes such as mortality and hospitalizations related to heart failure.

The study began on November 1, 2024, with its primary completion estimated for July 2024. The last update was submitted on June 28, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential findings that could impact clinical practices.

The study’s outcomes could influence Bayer AG’s stock performance by providing insights into vericiguat’s effectiveness, potentially boosting investor confidence. In the competitive landscape of heart failure treatments, positive results could position Bayer favorably against rivals and enhance its market share.

The study is ongoing, with further details available on the ClinicalTrials portal.